Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Dronabinol/palmitoylethanolamide (Primary) ; Dronabinol
- Indications Gilles de la Tourette's syndrome
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors SciSparc
- 23 Nov 2023 Planned End Date changed from 1 Oct 2024 to 1 Aug 2025.
- 23 Nov 2023 Planned primary completion date changed from 1 Jun 2024 to 1 Aug 2025.
- 23 Nov 2023 Planned initiation date changed from 1 Jun 2023 to 1 Feb 2024.